Saniona appoints Thomas Feldthus executive Vice President
Saniona, a leading biotech company within ion-channel research, today announced the appointment of Thomas Feldthus as executive vice president and CFO of the Company. He has until now served as CFO for Saniona in parallel with his work as CFO in WntResearch. From June 1, 2015, he will work full time in Saniona with an initial focus on preparing the company for a listing at OMX small cap in Stockholm.
“I believe that Saniona has a prosperous future and I am pleased that I now can dedicate all my time to develop the company further. We are making significant progress in the laboratories. We continue to have discussions with partners about potential new collaborations and we are enjoying an increased interest from investors. In the first quarter alone the number of investors grew from 777 to 1,489. We will now start the preparation for a possible listing on NASDAQ OMX Stockholm in 2016,” says Thomas Feldthus, EVP and CFO of Saniona.
In addition to his business development and financial responsibilities, Thomas Feldthus will assume the responsibility for the IR-activities and prepare the company for a potential listing at OMX small cap in Stockholm.
“Thomas and I have had a fantastic teamwork since the foundation of Saniona in 2012 where Thomas with his outstanding experience in business development, finance and IR has played well together with my experience within life science research and pharma partnering. I trust that we together will be able to create significant value for our shareholders in the coming period through progress in our programs and partnerships as well as in our investor relations activities,” says Jørgen Drejer, CEO of Saniona.
For more information please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com
About Saniona
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with major pharmaceutical companies including Pfizer Inc., as well as Saniona’s Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Idec Inc. Saniona is based in Copenhagen, Denmark, where it has a research centre of high international standard and 18 employees. Saniona is listed at AktieTorget since April 2014 and has about 1,500 shareholders. The company’s share is traded under the ticker SANION. Read more at www.saniona.com.
Tags: